Diseases

Pharma & Healthcare

Description:

Tularaemia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Tularaemia - Pipeline Review, H1 2016’, provides an overview of the Tularaemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tularaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tularaemia
- The report reviews pipeline therapeutics for Tularaemia by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- The report reviews key players involved Tularaemia therapeutics and enlists all their major and minor projects.
- The report assesses Tularaemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
- The report summarizes all the dormant and discontinued pipeline projects.
- The report reviews latest news related to pipeline therapeutics for Tularaemia.

Reasons to buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Identify and understand important and diverse types of therapeutics under development for Tularaemia.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Tularaemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

**Table Of Contents:**

- Table of Contents
- Table of Contents 2
- List of Tables 5
- List of Figures 5
- Introduction 6
- Global Markets Direct Report Coverage 6
Product Description 54
Mechanism of Action 54
R&D Progress 54
Tularaemia - Recent Pipeline Updates 55
Tularaemia - Dormant Projects 74
Tularaemia - Discontinued Products 75
Tularaemia - Product Development Milestones 76
Featured News & Press Releases 76
Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 76
May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 77
Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables
Number of Products under Development for Tularaemia, H1 2016 8
Number of Products under Development for Tularaemia - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Tularaemia - Pipeline by Aradigm Corporation, H1 2016 16
Tularaemia - Pipeline by Arno Therapeutics, Inc., H1 2016 17
Tularaemia - Pipeline by DynPort Vaccine Company LLC, H1 2016 18
Tularaemia - Pipeline by Emergent BioSolutions Inc., H1 2016 19
Tularaemia - Pipeline by EpiVax, Inc., H1 2016 20
Tularaemia - Pipeline by Grifols, S.A., H1 2016 21
Tularaemia - Pipeline by Merck & Co., Inc., H1 2016 22
Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Tularaemia Therapeutics - Recent Pipeline Updates, H1 2016 55
Tularaemia - Dormant Projects, H1 2016 74
Tularaemia - Discontinued Products, H1 2016 75

List of Figures
Number of Products under Development for Tularaemia, H1 2016 8
Number of Products under Development for Tularaemia - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Top 10 Targets, H1 2016 25
Number of Products by Stage and Top 10 Targets, H1 2016 25
Number of Products by Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31

Companies Mentioned:

Aradigm Corporation
Arno Therapeutics, Inc.
DynPort Vaccine Company LLC
Emergent BioSolutions Inc.
EpiVax, Inc.
Grifols, S.A.
Merck & Co., Inc.
Tetraphase Pharmaceuticals Inc.

License Types:

Single User License (PDF)

• This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Site License (PDF)**

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Global License (PDF)**

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

**Source URL:** https://www.marketresearchreports.com/global-markets-direct/tularaemia-pipeline-review-h1-2016

**Links**